Recro Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>RP</div>
REPH -- USA Stock  

USD 3.70  0.45  13.85%

The next fiscal quarter end is expected on the 31st of December 2020. The stock goes through an active upward rally. Because some millenniums are getting more into healthcare space, we are going to concentrate on the feasibility of inclusion Recro into your portfolio. We will examine the reasons why it is still possible for the company to generate above-average margins given the current economic outlook.
Published over a month ago
View all stories for Recro Pharma | View All Stories
Will Recro Pharma price rise in January?
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Recro Pharma has an asset utilization ratio of 53.52 percent. This implies that the company is making $0.54 for each dollar of assets. An increasing asset utilization means that Recro Pharma is more efficient with each dollar of assets it utilizes for everyday operations.
What is the right price you would pay to acquire a share of Recro Pharma? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

How important is Recro Pharma's Liquidity

Recro Pharma financial leverage refers to using borrowed capital as a funding source to finance Recro Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Recro Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Recro Pharma's total debt and its cash.

How Recro utilizes its cash?

To perform a cash flow analysis of Recro Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Recro Pharma is receiving and how much cash it distributes out in a given period. The Recro Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Recro Pharma Net Cash Flow from Operations is most likely to increase significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at 18.66 Million

Payment of 1352 shares by Ryan Lake of Recro Pharma subject to Rule 16b-3

Legal trades by Recro Pharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Recro insider trading alert for payment of common stock by Ryan Lake, Chief Financial Officer, on 20th of January 2021. This event was filed by Recro Pharma Inc with SEC on 2021-01-20. Statement of changes in beneficial ownership - SEC Form 4. Ryan Lake currently serves as senior vice president - finance, chief accounting officer of Recro Pharma [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Recro a risky opportunity?

Let's check the volatility. Recro is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Recro (NASDAQ:REPH) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. locking in a share of a Recro Pharma stock makes you a part-owner of that company.

Recro Pharma Current Consensus

Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Recro Pharma. The Recro consensus assessment is calculated by taking the average estimates from all of the analysts covering Recro Pharma

Strong Buy
2
Strong Buy2100.0
Buy00.0
Hold00.0
Sell00.0
Strong Sell00.0

Will Recro drop impact its fundamentals?

The semi variance is down to 13.28 as of today. Recro Pharma shows above-average downside volatility for the selected time horizon. We advise investors to inspect Recro Pharma further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Recro Pharma future alpha.

The Bottom Line

While many of the other players in the drug manufacturers?specialty & generic industry are either recovering or due for a correction, Recro may not be as strong as the others in terms of longer-term growth potentials. The inconsistency in the assessment between current Recro valuation and our trade advice on Recro Pharma is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Recro Pharma.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Recro Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com